[Molecular mechanism of norcantharidin inducing apoptosis in liver cancer cells]
Gong-quan Li1, Shui-jun Zhang, Jian-feng Lü
1Department of Hepatobiliary Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Objective:
To elucidate the molecular mechanism of norcantharidin (NCTD) in inducing apoptosis of liver cancer cells so as to provide basic rationales for its application in liver cancer treatment.
Methods:
Liver cancer cell lines of SMMC-7721 and BEL-7402 were treated with NCTD. The cell growth inhibition was measured by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, cell death detected by trypan blue exclusion assay and apoptosis examined by Annexin V/PI staining and flow cytometry. The cleavage of caspase-9, -3 and PARP, and the expression of the anti-apoptotic Bcl-2 proteins were analyzed by Western blot.
Results:
The MTT results showed that, after a treatment with NCTD for 24, 48 and 72 h, the IC50 of NCTD in SMMC-7721 cell line was 12, 6 and 1.6 µg/ml respectively; in BEL-7402, the IC50 10, 4 and 2 µg/ml respectively. Trypan blue exclusion assay showed that NCTD mediated substantial cell death in two cancer cell lines. Apoptosis assay showed that, after a 12 h treatment with 10 µg/ml NCTD, 27% of SMMC-7721 cells were induced to undergo apoptosis, an increment of 20% over the untreated control cells (7%); 30% of BEL-7402 cells became apoptotic, an increment of 22% over the untreated control cells (8%). Western blot analysis showed that NCTD treatment potently induced the activation of caspase-9, -3 and the cleavage of PARP, and markedly down-regulated the expression of Bcl-2, Bcl-X(L) and Mcl-1.
Conclusion:
NCTD strongly inhibits liver cancer cell growth and potently induces apoptotic cell death in two liver cancer cell lines. The strong anticancer activity of NCTD may be induced through targeting multiple Bcl-2 anti-apoptotic family members.
Insights
Norcantharidin (NCTD) effectively inhibits liver cancer cell growth and induces apoptosis by targeting Bcl-2 family proteins. This study elucidates NCTD
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide.
- Developing novel therapeutic agents with potent anticancer activity is crucial for improving HCC treatment outcomes.
- Norcantharidin (NCTD) is a derivative of cantharidin with demonstrated antitumor properties.
Purpose of the Study:
- To investigate the molecular mechanisms by which NCTD induces apoptosis in liver cancer cells.
- To provide a scientific basis for the potential clinical application of NCTD in treating liver cancer.
Main Methods:
- Liver cancer cell lines (SMMC-7721 and BEL-7402) were treated with NCTD.
- Cell viability was assessed using MTT assays.
- Cell death and apoptosis were quantified via trypan blue exclusion and Annexin V/PI staining with flow cytometry.
- Protein analysis (caspase-9, -3, PARP, Bcl-2 family) was performed using Western blot.
Main Results:
- NCTD significantly inhibited the proliferation of both SMMC-7721 and BEL-7402 cell lines in a dose- and time-dependent manner.
- NCTD treatment led to substantial cell death and induced significant apoptosis in the tested liver cancer cells.
- Western blot analysis revealed that NCTD activated caspase-9 and -3, induced PARP cleavage, and downregulated anti-apoptotic proteins (Bcl-2, Bcl-X(L), Mcl-1).
Conclusions:
- NCTD exhibits potent anticancer effects against liver cancer cells by inducing apoptosis.
- The mechanism involves the activation of the intrinsic apoptotic pathway and modulation of Bcl-2 family proteins.
- NCTD holds promise as a therapeutic agent for liver cancer treatment.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
01:17The Extrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:30Apoptosis